Category Archives: Henan

Henan Proposes Standardizing and Consolidating Medical Services Pricing Items Across Four Clinical Categories – Public Consultation Open Through 17 September, With Parallel Cancellation Lists

Zhengzhou, China – 11 Sep 2026 – The Henan Provincial Healthcare Security Administration has released for public comment its draft plan to standardize and consolidate medical services pricing items in four clinical categories – digestive system, vascular and lymphatic system, maxillofacial surgery, and general treatment – together with matching lists of price items proposed for cancellation in each category. The consultation, issued under the national pilot program for deepening medical service price reform (Yi Bao Fa [2021] No. 41), accepts written or scanned feedback before 17 September 2026.

Policy Milestone

ItemDetail
Issuing AgencyHenan Provincial Healthcare Security Administration – Department of Medical Commodity Pricing and Tender Procurement
Announcement Date11 Sep 2026
Policy BasisNHSA and seven other departments’ Notice on Issuing the Pilot Program for Deepening Medical Service Price Reform (Yi Bao Fa [2021] No. 41); NHSA project‑establishment guidelines for medical service price items
ScopeStandardization and consolidation of price items across digestive system; vascular & lymphatic system; maxillofacial surgery; general treatment categories
Dual StructureEight attachments: 4 consolidation drafts + 4 cancellation drafts (one pairing per category)
Comment DeadlineBefore 17 September 2026 – written submission or electronic scan, bearing organizational seal or personal signature
ContactTel: 0371‑69690434; Email: hnsybjjgzc@126.com

Standardization & Consolidation Framework

  • Two‑Track Restructuring: For each of the four categories, the Administration has prepared both a draft of standardized/consolidated price items (Attachments 1–4) and a draft list of price items proposed for cancellation (Attachments 5–8) – signaling a deliberate slimming of Henan’s fragmented local price‑item catalog.
  • Category Pairing: Vascular and lymphatic system services are handled together as a single consolidated category, alongside digestive system, maxillofacial surgery and general treatment items.
  • National Guidelines Alignment: The restructuring implements the NHSA’s project‑establishment guidelines (立项指南) for medical service price items – part of the nationwide campaign to unify locally defined, inconsistently named service items under standardized national categories.
  • Pricing Reform Pilot Lineage: The plan operationalizes the 2021 eight‑department price reform pilot framework, which shifted the policy focus from item‑by‑item price adjustment toward structural standardization of what hospitals may charge and bill.
  • Draft Content: Specific item names, mappings and price levels are set out in the eight attachments and were not disclosed in the public notice itself.

Public Consultation Requirements

  • Eligible Submitters: Any organization or individual.
  • Format: Comments must be submitted in writing or as electronic scans to the Administration’s Department of Medical Commodity Pricing and Tender Procurement.
  • Authentication: Submissions must bear the official seal of the organization or the personal signature of the submitter; feedback is due before 17 September 2026.

Market Impact & Outlook

  • Catalog Rationalization: Consolidation paired with explicit cancellation lists will compress Henan’s billable service menu, eliminating overlapping, outdated or fragmented charge items – a prerequisite for transparent, comparable pricing across hospitals.
  • Hospital Billing Impact: Providers will need to remap billing systems and internal charge masters to the new standardized items, with abolished items requiring migration to consolidated equivalents.
  • National Convergence Signal: As more provinces issue guideline‑based restructuring drafts, Henan’s move reinforces the trajectory toward nationally uniform medical service price items, reducing cross‑province variation in how identical procedures are named and priced.
  • Price‑Level Uncertainty: The notice covers item standardization and consolidation, not the setting of new price levels; any subsequent price adjustments would follow separate provincial processes – details not disclosed.
  • Tight Window: The roughly six‑day comment period suggests the Administration intends to finalize the restructured catalog on a compressed timeline.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization and implementation of Henan Province’s standardized and consolidated medical services pricing items. Actual outcomes may differ due to risks including public feedback, revisions to draft consolidation and cancellation lists, national guideline updates, and provincial implementation timing. The drafts remain subject to revision and do not constitute final policy.-China Health Reform Pulse

Policy Source: http://ylbz.henan.gov.cn/2026/09-11/3418603.html

Henan Adjusts Medical Consumables Payment Standards for Cardiac Devices

Zhengzhou, Aug 28, 2026 — Henan Provincial Medical Security Bureau opened public consultations on adjusting medical insurance payment standards for select medical consumables, including coronary intervention balloon catheters and cardiac pacemakers, following provincial alliance procurement executions, while moving leadless pacemakers out of the negotiated consumables catalog into general management.

Policy Snapshot

AttributeDetail
IssuerHenan Provincial Medical Security Bureau
DocumentNotice on Soliciting Opinions on Adjusting Payment Standards for Some Medical Consumables Under Medical Insurance
ScopeCoronary intervention balloon catheters; cardiac pacemakers; related inter-provincial alliance procurement batches
Key changeLeadless implantable cardiac pacemaker removed from negotiated consumables catalog, reclassified as general consumable
Legal basisHenan Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Medical Consumables Catalog (2025) (Yu Yi Bao Ban [2025] No. 85)
Affected noticesYu Yi Bao Ban [2026] No. 35 (10 batches); Yu Yi Bao Ban [2026] No. 47 (2 batches)
Comment deadlineSept 12, 2026, 17:00 CST
ContactWang Minghua, 0371-69698064, hnybjyyc@126.com

Key Adjustments

The bureau proposed payment standard revisions for medical consumables covered under two provincial alliance procurement execution notices—one spanning 10 batches of coronary intervention balloons and related items, the other covering two batches of cardiac pacemakers. The most significant structural change involves the reclassification of the leadless implantable cardiac pacemaker from the negotiated consumables directory to general consumable management, effectively removing it from the separate negotiation track and subjecting it to standard reimbursement protocols.

Market Impact Analysis

The payment standard adjustments reflect the downstream policy synchronization that follows large-scale inter-provincial volume-based procurement for high-value cardiac devices. For manufacturers, the recalibration of reimbursement benchmarks will directly affect net pricing after insurance settlement, potentially compressing margins for coronary balloons and traditional pacemakers that were already subject to steep procurement-driven price cuts.

The reclassification of leadless pacemakers from negotiated to general consumable status is particularly consequential. Leadless pacemakers—premium devices that command significantly higher prices than conventional transvenous systems—had previously been shielded under the negotiated catalog, which typically allows for separate price agreements and more favorable reimbursement rates. Moving them to general consumable management signals a potential reimbursement downgrade, forcing manufacturers to absorb lower insurance payment ceilings or risk reduced hospital adoption as out-of-pocket costs rise for patients.

For hospitals and distributors, the adjustment clarifies the post-procurement reimbursement landscape, reducing administrative ambiguity but potentially tightening payment flows for high-end cardiac implants. The 15-day comment window suggests regulators intend to finalize standards by late September, leaving limited time for industry stakeholders to shape payment benchmarks.

Forward-Looking Statement

Industry analysts expect Henan’s template to be replicated across additional provinces that participated in the same inter-provincial procurement alliances, triggering a wave of payment standard harmonization for cardiac consumables in the fourth quarter of 2026. The leadless pacemaker reclassification may foreshadow a broader regulatory push to rationalize reimbursement tiers for premium implantable devices, potentially extending to structural heart and neurostimulation products. Companies with significant exposure to Henan’s cardiac device market should prepare for compressed reimbursement margins and evaluate pricing strategies that balance procurement compliance with sustainable hospital economics. Final rules are anticipated by late September or early October 2026.-China Health Reform Pulse

Policy Source: http://ylbz.henan.gov.cn/2026/08-28/3408750.html

Policy Analysis & Guidance: Henan’s Implementation of National Drug Procurement Results

Henan Province’s Medical Security Bureau has issued detailed guidelines for implementing the results of the tenth batch of national drug centralized procurement, alongside two additional procurement initiatives. The policies, effective from April 30, aim to reduce healthcare costs and ensure broader patient access to essential medicines.

Policy Breakdown

  • Scope: Includes national-level procurement results, a traditional Chinese medicine (TCM) alliance, and a regional alliance for primary care medications.
  • Implementation Timeline: Procurement cycles vary from one to two years, with annual contract renewals and provisions for extending cycles.
  • Supply Mechanism: Backup suppliers are integrated into the procurement framework to ensure continuity, even if primary suppliers fall short.
  • Pricing Rules: Clear guidelines for setting procurement prices, including benchmarks for non-primary suppliers and delisting criteria for non-compliant products.

Market Implications
The expanded procurement scope, including TCM and regional alliances, signals Henan’s push to rationalize drug pricing across categories. Analysts at Henan Healthcare Institute estimate a 15–20% reduction in procurement costs for participating institutions.

Industry Impact
Pharmaceutical companies must align with Henan’s pricing and supply frameworks to retain market access. The policy emphasizes annual performance reviews and penalties for non-compliance, raising stakes for contract fulfillment.

Looking Ahead
The April 30 implementation will test the province’s ability to balance cost reduction with supply stability. Stakeholders should monitor how backup supply mechanisms and price adjustments impact market dynamics.-China Health Reform Pulse

Policy Source: http://ylbz.henan.gov.cn/2025/04-08/3145778.html